Results 151 to 160 of about 21,936 (207)
Some of the next articles are maybe not open access.
The Function and Regulation of Platelet P2Y12 Receptor
Cardiovascular Drugs and Therapy, 2021In addition to the key role in hemostasis and thrombosis, platelets have also been wildly acknowledged as immune regulatory cells and involving in the pathogenesis of inflammation-related diseases. Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely ...
Xia Cao
exaly +3 more sources
Thrombosis and Haemostasis, 2010
SummaryThe thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention. However, the optimal level of P2Y12 blockade to effectively inhibit platelet function is unknown.
Robert Buckland +2 more
exaly +3 more sources
SummaryThe thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention. However, the optimal level of P2Y12 blockade to effectively inhibit platelet function is unknown.
Robert Buckland +2 more
exaly +3 more sources
Effect of P2Y12 inhibitors on inflammation and immunity
Thrombosis and Haemostasis, 2015SummaryPlatelet P2Y12 inhibitors form a major part of the treatment strategy for patients with acute coronary syndromes (ACS) due to the importance of the platelet P2Y12 receptor in mediating the pathophysiology of arterial thrombosis. It has been increasingly recognised that platelets also have a critical role in inflammation and immune responses ...
Mark Thomas, Robert Storey
exaly +3 more sources
P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor
Heart, 2021Objective To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing percutaneous coronary intervention (PCI).
Juwon Kim +30 more
openaire +2 more sources
Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor
Journal of Cardiovascular Pharmacology, 2022Abstract: The use of a P2Y12 inhibitor as a component of dual antiplatelet therapy in patients with an acute coronary syndrome (ACS) is well established. However, the P2Y12 inhibitors currently available have pharmacokinetic limitations due to delayed absorption, lack of enteral access for administration with oral formulations, need for ...
Craig J, Beavers +2 more
openaire +2 more sources
Hämostaseologie, 2009
SummaryThe P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin.
J-P, Collet, G, Montalescot
openaire +2 more sources
SummaryThe P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin.
J-P, Collet, G, Montalescot
openaire +2 more sources
2023
Abstract Adenosine diphosphate P2Y12 receptor antagonists inhibit platelet activation and subsequent aggregation. These agents may be used either alone or as part of dual antiplatelet therapy regimens with aspirin. P2Y12 inhibitors have proven useful in the treatment and prevention of several atherosclerotic cardiovascular conditions ...
Manan Pareek, Deepak L. Bhatt
openaire +1 more source
Abstract Adenosine diphosphate P2Y12 receptor antagonists inhibit platelet activation and subsequent aggregation. These agents may be used either alone or as part of dual antiplatelet therapy regimens with aspirin. P2Y12 inhibitors have proven useful in the treatment and prevention of several atherosclerotic cardiovascular conditions ...
Manan Pareek, Deepak L. Bhatt
openaire +1 more source
Current Opinion in Hematology, 2009
The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists.
openaire +2 more sources
The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists.
openaire +2 more sources